Search results

Memorises Bio is a therapeutic antibody discovery company spun out of Memo Therapeutics. We investigate human immune responses and translate them into therapeutic antibodies, combining deep repertoire capture with large-scale functional screening.

Based in Epalinges, Pilatus Biosciences focuses on developing a first-in-class antibody targeting metabolic checkpoints. The company is transforming cancer treatment by developing innovative therapies that strengthen the immune system to fight cancer.

Step Pharma is a clinical stage precision oncology company. Dencatistat (STP938) is a first in class, oral, selective CTPS1 inhibitor currently in Phase I/II clinical development in essential thrombocythemia, biomarker selected solid tumours and relapsed/refractory lymphoma.

imunaris is a forward-thinking Swiss startup committed to facilitating commercial access for pharmaceuticals, medical devices, and diagnostics. With a focus on agile and efficient methods, we offer tailored solutions to conquer the complexities of the Swiss healthcare market.

nuantic offers AI-guided lead optimization to biotech and pharma customers developing protein- and peptide-based therapeutics. We're able to optimize affinity, developability and aspects of immunogenicity with outstanding success rates with 10x less effort as compared to traditional methods.

FoRx Therapeutics is a clinical-stage company that develops next-generation small molecule therapeutics targeting DNA Replication Stress pathways for anti-cancer therapy. The lead program is a highly potent and selective PARG inhibitor, FORX-428, which  moved into clinical Phase 1 in H2 2025.

Humion is a Swiss cancer therapeutics biotech developing TCR-based T-cell therapies for solid tumors. We decode the immune responses of cancer super responders to identify validated tumor targerts and translate them into precise, patient-derived therapeutics.

Solvias is a Contract Research, Development & Manufacturing Organization We offer comprehensive, high quality and fast analytical services for small molecule API, biologics and cell & gene therapies, by ensuring the interplay of outstanding experts in every required individual discipline.

Jantar is a clinical R/D company in the field of chronic rhinosinusitis. Its asset is dicholine succinate for which clinical proof-of-concept has been established. DISU represents a differentiated new drug with strong safety, rapid efficacy and clear potential for global consumer health leadership.

Hemastatx brings innovation to patients with severe, underserved bleeding conditions. HMX-001 is a first-in-class anti-ADAMTS13 antibody targeting the root cause of severe bleeds in (rare) von Willebrand factor (VWF) disorders. Hemastatx is a KU Leuven spinoff and part of the BaseLaunch portfolio.

Preclinical stage biopharmaceutical company, spin off of the European Diabetes Study Center (CeeD), dedicated to developing first-in-class biotherapies against diabetes and metabolic diseases, harvesting the breakthrough potential of the muscle secretome to regulate metabolism, a novel and unexplored approach

Biodelphis Therapeutics is a Swiss biotech startup, spinoff of EPFL. We developed a new generation of protease inhibitors with enhanced potency and safety, exhibiting all the qualities needed to become first-in-class drugs for the treatment of cancer, autoimmune diseases and bone diseases.

Enabling breakthrough medicines achieve the outcomes they were designed for. We unlock the full therapeutic potential of innovative drug candidates through our next-gen nanomedicine delivery platform. We want to establish our biovectors as the universal standard for targeted therapeutic delivery.

Minaris is a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization. With more than 25 years of CGT development and manufacturing expertise and more than 40 years in biosafety testing, Minaris combines deep legacy experience with state-of-the-art GMP facilities.

RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness and aims to restore vision and transform the lives of patients worldwide.

Headquartered in Switzerland with global operations, Space Peptides provides end-to-end pharmaceutical Peptide CRDMO services - covering discovery, process development, and GMP manufacturing. In addition, our portfolio comprises a broad range of generic Peptide APIs.

Opterion Health AG is a privately owned, Swiss-based, clinical-stage biotech company developing innovative therapies for peritoneal dialysis (PD).

Nanolynx Biologics AG is developing first-in-class conditionally active nanobody-drug conjugates (CA-NDCs) that overcome the tissue penetration and toxicity limits of conventional ADCs, enabling safer and more efficacious therapies for hard-to-treat solid tumors.  

AzureCell is a Swiss regenerative cell therapy company leveraging two decades of pioneering neuroscience and cell‑engineering research at the University of Geneva to advance next‑generation allogeneic cell‑replacement therapies for the brain.

Streamlining complexity: with 15+ years experience (EU, US and Far East) in Oncology, Rare Diseases and Quality of Life Assessment, Naexture provides ad-interim leadership roles in Clinical Operations and Program Management to end-to-end operationalize clinical research programs.

GlioCART is a University of Basel spin-off focused on translating a dual-action CAR-T therapy for glioblastoma into clinical application by combining tumor targeting with immune microenvironment reprogramming. Our mission is to achieve durable clinical benefit for patients with glioblastoma.

Stallergenes Greer is a fully integrated global healthcare company specialising in the research, diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services.

CALDRE is a Switzerland based biotech spin-out focussed to revolutionize the way cholestatic-and fibrotic diseases are treated. We develop precise, liver-directed GalNAc-siRNAs to restore bile flow and prevent fibrosis - placing CALDRE in the fast-growing RNA-therapeutics segment of biotech.

Almac provides the most comprehensive global clinical supply chain solution in the marketplace. Guided by our extensive supply experience, we provide the physical resources and supportive technologies that ensure your clinical supply chain continually delivers across the globe.

SYDRA AG (Zurich) is a longevity biotech using a phenotype-first, AI-assisted “Hit-to-Target” early drug discovery platform. We discover small molecules (geroprotectors), validate in vivo (worms – aged mice), then map MoA to build partner-ready drug assets; plus science-backed supplements.

Mabylon is a clinical-stage company leading innovation in human-derived antibody therapeutics for severe allergies, inflammation, and neurological disorders. MY006, our first-in-class multi-specific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

Enantios is a Swiss startup revolutionizing molecular characterization with in-solution structural analysis of chiral complex molecules and biologics. Enantios delivers solutions for quality control and drug development in pharmaceutical, biotech, and chemical industries.

AND Biotech is a science-led company developing bioactive technologies that target the core systems of human resilience. We take promising compounds and translate them into clinically meaningful interventions. We develop scalable technologies that address biological decline, starting long before disease.

DiNABIOS bridges the gap "from lab to life." We offer human-based screening, phenotyping, and services across diverse tissues. Using proprietary 3D tissue engineering and our DiNAQUBE™ platform, we deliver precise efficacy and safety data to de-risk drug development and accelerate clinical success.

Ultimate Medicine is a Swiss preclinical biotech focused on preserving independence and quality of life for patients with Alzheimer's disease and other dementias.

TheraPPI Bioscience is a preclinical biotechnology company developing small molecules modifying protein interactions in oncology, rare diseases, and inflammation.  

Most cell and stem cell therapies fail beyond blood cancers because delivery cannot preserve function in solid organs. ClexBio’s biological platform enables safe, durable solid tissue replacement, unlocking regenerative therapies for liver failure, type 1 diabetes, and heart disease.

The Future Rewritten: Unlocking Genome Editing. By fusing directed evolution, high-throughput characterization, and AI, Nerai creates novel CRISPR editors, more precise and more powerful, making gene editing safer and accessible to more patients.

Exeris delivers custom solutions to support manufacturing of small molecules and recombinant proteins. We bring our project management, manufacturing and custom synthesis expertise to provide seamless supply to your project.

Tridek-One is a biotech start-up developing first-in-class CD31 agonist modalities designed to restore the immune balance.

Immitra Bio is a pre-seed stage therapeutic biotech company spun out of ETH Zürich. Immitra Bio is developing a platform for scalable, curative in vivo gene-editing therapies.

Beech Biotech is developing a novel treatment for preeclampsia, an severe unmet medical need that takes the lives of 70,000 women and 500,000 babies each year. The company is developing a novel placenta-impermeable antibody and works with a network of expert industry consultants and contractors.

Umlaut.bio develops first-in-biology small molecules focusing on tRNAs that protect signalling transduction mRNAs from degradation. Addressing this previously undrugged fundamental biochemical principle  could be able to selectively prevent the growth of cancer as well as  proinflammatory cells.

MicThera harnesses microbes to discover breakthrough therapeutics, leveraging microbial bioactive molecules -synthetically produced- to overcome therapy resistance. Our discovery platform unlocks microbial-inspired therapeutics to develop innovative treatments.

At FloBiotech, we develop advanced human brain cell models to unlock new therapeutic and diagnostic pathways for neurodegenerative diseases. We address neurodegeneration at its core to enable earlier risk reduction in drug development, improved translational success, and scalable pipeline expansion.

A swiss-based company developing therapeutics for chronic inflammation. We are engineering novel bi-functional Duokine therapeutics, rationally designed to simultaneously target distinct immune cell populations and disease-relevant pathways.

Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. The company targets validated biology in respiratory and dermatology.

Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development.

metaLead is an early-stage life science spinout from the University of Zurich, supported by reputable investors, i.e., BaseLaunch. We aim to revolutionize the treatment landscape for metal-related diseases, starting with Wilson disease, leveraging our platform of novel, rationally designed peptides.

Leman Biotech is a clinical-stage biotech advancing immunotherapy via metabolic reprogramming. Its META 10 platform reverses T-cell exhaustion to unlock unprecedented efficacy and durability in oncology and autoimmune diseases, delivering a highly effective, scalable, and accessible approach.

Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators.

Abbmira Therapeutics is a Basel-based biotech founded by experienced scientists and entrepreneurs in September 2024. Abbmira develops first-in-class small molecules to fine-tune native immunity to treat difficult-to-treat cancers and chronic diseases.

InVirtuoLabs is pioneering the next-generation laboratory by integrating AI with molecular simulations to revolutionize drug discovery. Our platform generates up to 1 billion novel molecules per day, rapidly screening and identifying the most promising ligands for specific biological targets.

Avenza Consulting has been created to support pharma, biotech companies, startups to develop and grow by offering Strategic Consulting, R&D services to foster innovation, Program & Portfolio Management to optimize projects, and Operational Excellence to streamline processes.

Signal26 Biotherapeutics is a biotechnology startup dedicated to advancing a novel antibody for treating psoriasis. In collaboration with interdisciplinary experts, we lead research into interleukin 26 (IL-26) and its role in the signalling pathways involved in autoimmune disorders.

Juvion develops advanced therapeutics aimed at preserving neuron-muscle connectivity, tackling immobility and sarcopenia to extend healthspan.

Release Therapeutics SA (RTx) is a Swiss biotech company developing the first intracerebral encapsulated cell technology (ECT) platform for the treatment of severe genetic disorders of the central nervous system (CNS).

Enzene is a fully integrated CIDMO with sites in Pune (India) & New Jersey (USA), offering discovery to commercial supply. Its EnzeneX™ FCCM™ tech leads next-gen biologics, aiming to cut mAb costs below $40/g by 2025. Learn more at www.enzene.com.

BeOne Medicines is a global oncology company developing innovative, affordable, and accessible cancer treatments worldwide. We expedite development of our diverse pipeline of novel therapeutics through strong internal capabilities and collaborations. Our 11,000 colleagues span six continents.

Justin Stindt Consultants is a consulting firm specializing in Strategy & Market Access advisory services for the pharmaceutical, biotech and medical device industries.

We are offering worldwide professional medical writing and related services to the pharmaceutical (human & veterinary), biotech, medical device and other industries, CROs and academic institutions. With over 20 years of experience in the field, we guarantee the best possible medical writing.

Founded in mid-2022, T-Oncology is a Swiss biotech startup dedicated to transforming cancer treatment through innovative therapies. Our Mission: Give hope to patients by creating advanced therapeutics that offer safe and more effective treatment options, affordable for patients worldwide.

Amporin is developing a new class of small molecule amyloid pore inhibitors as the first potential acute oral drugs to stop and reverse the progression of deadly degenerative diseases. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease.

Procavea Biotech is an ETH Spin-off company developing an innovative protein-based RNA delivery platform. Our focus is to generate siRNA therapeutics in extrahepatic disease areas that are currently unreachable.

Access2Health partners with biotechs, providing flexible, cost-effective support to maximise asset value. We offer strategic guidance in market potential, evidence generation, pricing, and value strategy, helping biotech leaders make informed decisions that strengthen their position with investors.

ICE Biopharma has 2 core businesses: in-licensing specialty and rare disease drugs for Europe and Canada, and operational consultancy to companies evaluating international Commercialization options. We want European and Canadian patients to have access to the breakthrough therapies they deserve.

Xcube.bio builds organizations with late-stage innovative biopharma companies to enable the European market entry of life changing therapies. We create partners' own commercial footprint and revenue streams. Unique value proposition that open and de-risk the European market for innovative therapies.

Allegria Therapeutics was founded in Basel in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches around biological targets that selectively modulate mast cells, Allegria plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases.

Complyomics supports Life Sciences companies in core areas as: Build and maintain robust Quality Systems in compliance with regulatory requirements. Provide externalized QA. Audits Develop expertise in Bioanalytical / Analytical areas Identify / assess / supervise sub-contractors Due diligence

Tandem Therapeutics (Spin-off ETH Zurich & PSI) is tackling the growing unmet medical need in treating fibrosis with precision extracellular matrix targeting. Our novel peptide drug conjugates selectively target mechanical changes in the fibrotic extracellular matrix to potentially halt progression.

ARTBIO is a clinical-stage radiopharmaceutical company focused on developing a new class of alpha radioligand therapies (ARTs) to transform cancer treatment. ARTBIO's approach centers on utilizing the alpha-emitting isotope Pb212 to target cancer cells while minimizing damage to healthy tissues.

HekeTiss, a UNIGE/HUG spin-off, enhances lives by pioneering cell-therapy treatments for ulcerative skin conditions. Innovating for a healthier tomorrow.

FatiAbGen International is the Swiss subsidiary of FatiAbGen Inc., established in Korea in 2020. We engineer best in class antibodies tailored for multiple modalities such as ADCs and bi-specifics. We then develop targeted molecules to address high unmet need diseases in oncology and immunology.

NewBiologix is a company developing a proprietary and breakthrough platform for the advanced engineering of cell lines. The company is committed to improving the production of viral vectors used in gene therapy by combining an innovative bioinformatics platform with advanced R&D experimentation.

Remora Biotech is a biotherapy portfolio company with a track record of successfully turning science into life-changing biotherapies. We focus on high-impact therapeutic areas including oncology, immunology, regenerative / aesthetic medicine and cell and gene therapies.

Luminance Health is a premium life science consultancy providing personalized support across the entire value chain. We provide cross-functional strategic and hands-on support to develop, register, market and bring innovative products to market.

Curie.Bio is a $1.2B VC founded to discover and develop important new medicines. We do that by investing directly into existing companies, creating focused spinouts, and helping founders build companies from scratch. Our team of >100 full-time drug hunters provides hands-on support to founders.

APR Applied Pharma Research s.a. (wholly owned by Relief Therapeutics Holding AG, SIX: RLF.SW), is a B2B Swiss-based international biopharma focused on development and global commercialization of innovative, patent protected products designed to address unmet needs.

At Stämm we develop accessible, plug & play biomanufacture solutions; allowing an automatized, continuous and more efficient production of biologics and cell therapies while managing media conditions. We have reinvented biomanufacturing by providing an alternative to the known biomass production.

Menarini Biotech (“MBH”) is a fast-growing, agile, fully integrated CDMO for biologics. Established in 2003, MBH's mission is to provide fast and efficient, yet very customer-centric, world-class, high-quality, services for biotech companies. Our Q system complies with AIFA/EU GMP requirements.

Our mission is to develop novel formulations for biological drugs enabling direct and exclusive delivery to diseased cells and tissues. Our concept for the oligonucleotide drug family of siRNAs creates a broad potential for this new generation of drugs, having recently emerged in the drug landscape.

Salvina Therapeutics is developing antibodies with a novel approach for targeting TNF and TNF superfamily members with the aim of improving their safety and efficacy, and facilitating the generation of novel bispecific therapies.

Porton Pharma Solutions, a global company with R&D, and GMP-compliant manufacturing facilities across US, EU and China, provides customer-centric innovative, and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (ADCs, PDCs, etc.) from pre-clinical to commercial stage.

Bavarian Nordic is a fully integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines. Our manufacturing site for oral vaccines is located in Thörishaus, 15 km southwest of Bern.

Altorfer Engineering is a specialized contractor and consulting company. We provide expertise in engineering and project management services, and technology transfers. Our focus is on developing and managing aseptic formulation and fill-finish processes tailored to your receiving sites.

Blueprint Medicines is a global precision therapy company inventing life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, our medicines selectively target genetic drivers, with the goal of staying one step ahead of disease.

Infinity Communications works with start-up and growth-stage healthcare companies to deliver insights-driven, strategic communications. We add value by developing content and material to raise your company profile, attract new investors and engage audience groups across the health ecosystem.

B Squared helps biotech and cell & gene therapy companies navigate complex CMC, manufacturing, and sourcing challenges. We bring hands-on expertise, real-world solutions, and a no-nonsense approach to getting things done.

Swiss Bioscience was established in 2014 in Switzerland and is specialized in producing pharmaceutical quality grade stems cells under cGMP* conditions. The cells are isolated from human adipose tissue to produce SVF which is then purified and expanded to produce hADSCs.

CELLnTEC technologies enable science and industry to develop innovations in stem cell research, regenerative medicine, cell-based therapies, and beyond. The company is a pioneering developer of chemically defined, animal and human components-free precision media.

Caland SA provides a professional, confidential, competitive and impeccable service of pharma-grade CO2 extraction, distillation and cannabis formulation based on GMP requirements. A modern production line, coupled to a qualified ERP, ensures uncompromising quality of all products and services.

Curare specializes in translational and clinical pharmacology, increasing confidence in therapeutics translation from the bench to clinical proof‑of‑concept, and enhancing early stage decision-making. Expertise tailored to your needs, from small biotech to pharma.

MRGN Advisors was established in 2015 to advise CEOs, boards and investors on portfolio strategy, commercial and market access development, partnering and investment advisory in pharma, biologicals, vaccines, med tech and healthcare IT. Our motto: Even monkeys fall from trees — Japanese Proverb

Our goal is to deliver innovations in health care through cutting-edge tech and research, addressing challenges in antimicrobial therapies to improve patient outcomes. We are committed to delivering superior treatments that promote healing and improve quality of life globally.

Floratek Pharma is focused on drug discovery and preclinical development, enhancing the healing power of plants through the optimisation of existing natural compounds. The company pipeline comprises of anti-cancer and neurodegenerative disorder therapies as well as anti-aging dietary enhancements.

I work closely with my clients as a freelance science business development project manager. That said, Boehler Life Science Advice is not a typical consultancy, even though strategic planning and execution are important elements of how I support my clients.  

Qanatpharma (QP) is a Swiss clinical-stage biotech pioneering resistance artery medicine. Our Arteriome platform combines vascular biology, functional phenotyping and AI to discover novel drug targets and develop therapeutics for cardiovascular and neurological diseases.

Orio Therapeutics developed a technology based on protein engineering allowing to integrate a "built-in" delivery systems into any therapeutic protein. Orio Therapeutics has set as a priority for their first product the development of a cardioprotective drug for heart attack patients.

VACCENTIS AG is a Zurich-based investment company focused on the biotech and pharmaceutical sector. The entire research, production and sales activities are carried out by two highly specialized subsidiaries, VCC MEDICAL and FBM-Pharma, which focus on special methods of personalized medicine.

InkVivo Technologies combines its patented biomaterial platform with advanced manufacturing technologies to fabricate novel delivery systems that ensure controlled and prolonged release of active ingredients (e.g., small molecules, biologics and micronutrients).

Provectis Healthcare AG is a global healthcare company based in Basel and the commercial partner of choice to the innovative biopharma. We advance the innovation through launch, commercialization and brand building in Europe, Middle East and Asia.

FimmCyte is developing disease modifying therapies for chronic diseases through the direct elimination of diseased cells. FimmCyte has a pipeline of assets two of which are about to begin IND enabling studies, one for endometriosis and the second for organ fibrosis.